%0 Journal Article
%A Widjaja, Liam
%A Hornfeck, Johannes
%A Siegmund, Sophie C
%A Gildehaus, Franz J
%A Schmidt-Hegemann, Nina-Sophie
%A Wenter, Vera
%A Sheikh, Gabriel T
%A Klimek, Konrad
%A Casuscelli, Jozefina
%A Stief, Christian G
%A Zacherl, Mathias J
%A Werner, Rudolf A
%T Refining the clinical utility of [177Lu]Lu/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer.
%J European journal of nuclear medicine and molecular imaging
%V nn
%@ 1619-7070
%C Heidelberg [u.a.]
%I Springer-Verl.
%M DKFZ-2025-02262
%P nn
%D 2025
%Z epub
%X This study aimed to evaluate the efficacy and safety of Lutetium-177/Actinium-225 prostate-specific membrane antigen tandem radioligand therapy ([177Lu]Lu/[225Ac]Ac-PSMA tandem RLT) and to explore clinical and imaging-based predictors of treatment response to support individualized patient selection.This retrospective, single-center study included 23 patients with mCRPC who underwent Fluor-18 ([18F]F)-PSMA-1007 positron emission tomography/computed tomography (PET/CT) and subsequent tandem RLT. Whole-body tumor segmentation on PET/CT and standard laboratory values were acquired before treatment initiation. Primary endpoint was partial response (PR), defined as either a decline in prostate specific antigen of ≥ 50
%K PSMA-RLT (Other)
%K Prostate cancer (Other)
%K Tandem RLT (Other)
%K Targeted alpha therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41174098
%R 10.1007/s00259-025-07632-1
%U https://inrepo02.dkfz.de/record/305612